FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R&D

Genedata Selector™ used as central data hub to store, manage, and analyze complex diagnostic data enabling efficient clinical decision making

Basel, Switzerland, September 30, 2014

Genedata, a leading provider of advanced software solutions for drug discovery and related life science research, today announced that the FUNGITECT consortium has chosen Genedata Selector as its host-pathogen data analysis platform for next-generation sequencing (NGS) data. FUNGITECT is a European consortium dedicated to improving the treatment of invasive fungal diseases via individualized anti-fungal drug therapies. Genedata Selector supports this innovative research with a highly-scalable enterprise solution, which supports the integrative analysis of NGS and related experimental data. With Genedata Selector, FUNGITECT researchers can process enormous NGS datasets, extract relevant biological information and transition data to knowledge in support of the consortium’s goals.

Integrated Platform for Fungal Analysis Accelerates Innovative Drug Discovery
Fungal infections represent a significant medical problem, resulting in significant healthcare costs worldwide. Invasive fungal disease is a leading cause of morbidity and mortality in severely immunocompromised individuals such as bone-marrow and organ transplant recipients, preterm neonates, and patients with AIDS. These wide-ranging patient populations require stratified and timely administration of the most appropriate antifungal therapy. FUNGITECT will contribute to the development of such optimized and individualized therapeutic approaches that fight fungal pathogens.

 “Genedata Selector is key to FUNGITECT’s success,” said Prof. Thomas Lion, FUNGITECT’s project coordinator. “The solution will uniquely integrate diagnostically important characteristics of fungal infections, ranging from standardized sample collection to analysis of complex molecular data and result sharing. Selector’s ability to process big data sets will enable efficient clinical decision-making.”

Using sophisticated algorithms, Genedata Selector will serve as FUNGITECT’s central data management and analysis platform for biomarker development, diagnostics, and therapy support. The platform enables the integration of phenotype and genotype information and offers tools for statistical cross-omics analysis, and will thus facilitate efficient bio-marker prediction and target identification. Designed for scientists and clinicians alike, Genedata Selector:

  • manages molecular profiles of host-pathogen interactions
  • provides tools to assess pathogen resistance mechanisms
  • includes algorithms for rapid host and pathogen profiling
  • reliably predicts biomarkers and molecular targets
  • provides secure web-based data submissions and interactive data analyses

As part of the collaboration with the FUNGITECT consortium, the platform will be further developed to support the integration of existing human susceptibility markers, and re-annotation of genomes as references for functional reconstruction of the host-pathogen systems and their interactions.

“We are excited about our collaboration with the FUNGITECT consortium as it again validates that Genedata Selector can support a wide range of omics-based research projects,” noted Dr. Othmar Pfannes, CEO of Genedata. “Genedata remains committed to supporting innovative research projects with its scalable and modular computational platforms.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. Follow Us on LinkedIn